Furthermore, we found that a high infiltrating level of CD8+T cells was significantly associated with longer PFS in RCC patients who received immunotherapy in the SYSUCC immunotherapy cohort (HR 0.45, p=0.033, figure 3D). Here, CD8A is linked to renal cell carcinoma.